Problems and solutions in the evaluation of hormone receptors in breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2433-2435

  Allred, D Craig ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE; RNA; TAMOXIFEN; PROGESTERONE RECEPTOR;

ADD ON THERAPY; ADJUVANT THERAPY; BREAST CANCER; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EDITORIAL; EVALUATION; HORMONAL THERAPY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MEDICAL PRACTICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; METASTASIS; NEOPLASM; NOTE; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 45149096256     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.7800     Document Type: Editorial

References (25)

1. Badve S, Baehner FL, Gray R, et al: Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
2. Goldstein L, O'Neill A, Sparano JA, et al: E2197:Phase III (AT (doxorubicin/docetaxel) vs AC (doxorubicin/cyclophosphamide) in the adjuvanat treatment of node positive and high risk node negative breast cancer. J Clin Oncol 23:512, 2005 (suppl; abstr XXXX)
3. Allred DC, Harvey JM, Berardo MD, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
4. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
5. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
6. Mathews AW: Bad cancer tests drawing scrutiny. Wall Street Journal, 2008, pp B1-B2
7. Rhodes A, Jasani B, Balaton AJ, et al: Immunohistochemical demonstration of oestrogen and progesterone receptors: Correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53:292-301, 2000
8. Cheang MC, Treaba DO, Speers CH, et al: Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637-5644, 2006
9. Mohsin SK, Weiss H, Havighurst T, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17:1545-1554, 2004
10. Press M, Spaulding B, Groshen S, et al: Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids 67:799-813, 2002
11. Love RR, Duc NB, Allred DC, et al: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20:2559-2566, 2002
12. Allred DC, Brown P, Medina D: The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 6:240-245, 2004
13. Allred DC, Mohsin SK: ER expression is not bimodal in breast cancer. Am J Clin Pathol 124:474-476, 2005
14. Collins LC, Botero ML, Schnitt SJ: Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: An analysis of 825 cases. Am J Clin Pathol 123:16-20, 2005
15. Swanson PE, Schmidt RA: Beneath the surface of the mud, part II: The dichotomization of continuous biologic variables by maximizing immunohistochemical method sensitivity. Am J Clin Pathol 123:9-12, 2005
16. Zhang D, Salto-Tellez M, Putti TC, et al: Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79-84, 2003
17. Chung GG, Zerkowski MP, Ghosh S, et al: Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 87:662-669, 2007
18. Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74:1445-1451, 1996
19. Clahsen PC, van de Velde CJ, Duval C, et al: The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 25:356-363, 1999
20. Phillips T, Murray G, Wakamiya K, et al: Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 15:325-331, 2007
21. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
22. Goetz MP, Suman VJ, Ingle JN, et al: A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12:2080-2087, 2006
23. Ma XJ, Hilsenbeck SG, Wang W, et al: The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611-4619, 2006
24. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616, 2004
25. Oh DS, Troester MA, Usary J, et al: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656-1664, 2006